You can purchase 2T and 40T packs of ImmuView® COVID-19 Ag Home Test on Amazon. The ImmuView® COVID-19 Antigen Home Test is intended for the detection of SARS-CoV-2 (the virus that causes COVID-19). This self-administered test is for individuals ages 14 years and older. Adult-collection is required for testing children ages 2-13 years old. EASY TO USE AND QUICK RESULTS:.... Read Full Article >
The U.S. FDA has granted Emergency Use Authorization for CTK Biotech’s ImmuView® COVID-19 Antigen Home Test On December 20th, CTK Biotech obtained the FDA’s Emergency Use Authorization for their ImmuView® COVID-19 Antigen Home Test, a few months after being the first to receive the WHO Emergency Use Listing for their international brand, OnSite® COVID-19 Ag Self Test. The FDA EUA.... Read Full Article >
On July 18th 2022, CTK Biotech’s OnSite® COVID-19 Ag Self Test received WHO Emergency Use Listing for meeting WHO’s quality, safety, and performance requirements. CTK’s COVID-19 Ag Self Test is the first in the market to receive this Pre-Qualification. This milestone accomplishment reflects CTK’s 20-plus years of experience in providing best-in-class products across the globe. Read more about the WHO’s.... Read Full Article >
The Philippines FDA has granted approval of the CTK’s OnSite COVID-19 Ag Self-Test for its high quality and excellent performance.
We’re pleased to announce that CTK’s Onsite COVID-19 Ag Rapid Test has been granted WHO Emergency Use Listing! The OnSite COVID-19 Ag Rapid Test is deemed to meet WHO quality, safety, and performance requirements and is now eligible for relevant procurement agencies and the Member States. To learn more about CTK’s OnSite COVID-19 Ag Rapid Test
CTK Biotech has obtained the CE mark for our OnSite COVID-19 Ag Self Test. CTK will begin shipping this new test to the countries that accept the CE mark this month. The OnSite COVID-19 Ag Self Test is a single-use lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasal swab specimens from individuals suspected of COVID-19..... Read Full Article >
CTK’s goal during the current COVID-19 pandemic is to provide quality diagnostic tools for the detection of SARS-CoV-2, such as the Aridia Real-Time COVID-19 PCR Test. As new SARS-CoV-2 variants are identified, CTK has been working on confirmation studies to ensure that the performance of the Aridia COVID-19 Real-Time PCR Test isn’t affected by these mutations. The Aridia COVID-19 Real-Time.... Read Full Article >
CTK’s OnSite® COVID-19 Ag Rapid Test is on the EU Common List and EU Mutual Recognition List! Our test meets the requirements for both Nasal and Nasopharyngeal specimens for individuals suspected of COVID-19 within the first seven days of the onset of symptoms. The EU Common List requires that rapid antigen tests meet a minimum performance of ≥ 90% sensitivity.... Read Full Article >
As more and more variants are emerging, CTK’s commitment to ensure that CTK’s OnSite® COVID-19 Ag Rapid Test isn’t affected by these mutations is ongoing. We analyzed the NP mutations present in the California, Nigeria, and India/Delta variants and mapped them on the SARS-CoV-2 NP protein recognized by CTK’s OnSite® COVID-19 Ag Rapid Test using ELISA and peptide scanning. We found that.... Read Full Article >
CTK’s goal is to provide a Complete COVID-19 Diagnostic Solution and support market needs as the COVID-19 pandemic progresses. The COVID-19 market is ever-changing but currently can be segmented into: Increase testing needs as cases continue to fluctuate around the world: CTK’s Aridia COVID-19 Real-Time PCR Test detects SARS-CoV-2 B.1.1.7 with the same LOD (≤ 10 RNA copies per reaction) as.... Read Full Article >
The performance of the OnSite® COVID-19 Ag Rapid Test by CTK was evaluated using sample material from nasopharyngeal swabs stored in viral transport media. The swabs were previously used to screen for SARS-CoV-2 using qPCR. The OnSite® COVID-19 Ag Rapid Test sensitivity was between 86-90% depending on the viral load*. The study used leftover sample material selected from samples sent.... Read Full Article >
CTK is proud to provide a Complete COVID-19 Management Solution with the addition of our COVID-19 Antigen Rapid Test! See below for details! OnSite COVID-19 Ag Rapid Test Cat# R0182C Early diagnosis by detecting viral components within 1 week of symptoms High specificity ensures quick isolation of positive individuals Results in 15-20 minutes Doesn’t provide information on immune.... Read Full Article >
CTK’s vision is to provide quick and accurate solutions for every possible clinical scenario, and we continued to deliver on that mission with the development of our Aridia COVID-19 PCR kit for confirmation and our COVID-19 IgG/IgM Rapid Test for screening. This would not have been possible without the hard work and dedication of our employees. With our same level.... Read Full Article >
Introducing CTK Biotech’s New Immunofluorescence Analyzer and New Immunofluorescence Incubator! Accurate, flexible and user friendly! *Reach us through our website, contact your official CTK distributor, or e-mail us directly at info@ctkbiotech.com!
Thank you for visiting us at AACC 2018. We will see you at the end of August for the 5th International Conference on Neglected Tropical & Infectious Diseases in Boston, USA. In the meantime, we would love to get your feedback on the instruments we featured: ALTA ELISA Reader ALTA Microplate Washer ALTA Rapid Test Reader See you soon!
Tropical Disease Watch at CTK: Tropical diseases are a class of infectious diseases named after the hot, humid climates in which they tend to be most prevalent. The majority of tropical diseases are spread by mosquitoes and are most common during the rainy season, however due to rising global temperatures transmissions are now occurring year-round. A Call to Action Here.... Read Full Article >